Who We Are
We eliminate the infrastructure bottleneck in Digital Health Twin development.
CaraOmics provides EU-compliant MLOps infrastructure for researchers and pharmaceutical companies building Digital Health Twins. We reduce the time, cost, and regulatory complexity of DHT development so more twins reach the clinic, for more diseases, for more patients.
Explore Our ScienceThe team leading our vision forward.
Colm Coffey
Co-founder & CEO
Originally from Ireland and now based in Amsterdam, I help companies in regulated industries make the most of AI - from initial concept and experimentation all the way through to production deployment on the cloud.
My journey started at the intersection of biomedical engineering and software, working with industry leaders like Johnson & Johnson, AbbVie, and Medtronic. I've also contributed to innovative startups including ClinCapture (San Francisco), smoothOp (Ireland), and Connected Health (Amsterdam).
A recurring challenge I observed: 87% of organizations report they don't have a clear understanding of GDPR and AI Act requirements. This hesitation compounds when dealing with medical products. It drove me to build CaraOmics - a platform with compliance baked in.
Edouard Schneiders
Co-founder & COO
I'm Edouard, Co-founder at CaraOmics. Before embarking on this journey, I founded an AI startup through the global VC Antler. My experience is rooted in deep tech, having helped define and sell €100M+ lithography machines at ASML.
Leadership is at my core. I previously led a team of 37 engineers to victory at SpaceX's Hyperloop competition - twice. I understand how to translate complex technology into commercial value and build the high-performing teams necessary to deliver it.
Though Dutch by nationality, I grew up globally, which shaped my adaptability and international perspective. I thrive in challenging environments and am passionate about technology and doing good for society.
The convergence that made Digital Health Twins possible.
Human Genome Project Completed
After 13 years of international collaboration, the full human genome was sequenced for the first time. The biological blueprint needed to build patient-level computational models became available.
FDA Clears AI Companion Diagnostics
US regulators acknowledged that AI could play a direct role in clinical decision-making, clearing the first wave of AI-assisted companion diagnostics for targeted cancer therapies.
GDPR and the First Autonomous AI Diagnostic
The EU's General Data Protection Regulation entered force, establishing the data governance framework health AI would need. That same year, the FDA approved IDx-DR, the first AI system authorised to make a clinical diagnosis without physician oversight.
AlphaFold 2 Solves Protein Folding
DeepMind's AlphaFold 2 solved the 50-year-old protein folding problem at CASP14, predicting 3D protein structures with experimental accuracy. AI proved it could understand fundamental biology. The question of whether machines could model human biology stopped being theoretical.
Regulators Address Digital Twins Directly
The FDA published draft guidance on digital health technologies in clinical investigations, directly addressing digital twins. The EU Parliament approved the AI Act, creating the first comprehensive regulatory framework for AI in healthcare. For the first time, there was an explicit regulatory pathway for this technology.
The Industry Moves
The EU AI Act entered force. Novartis, Roche, and AstraZeneca expanded digital twin programmes. The FDA accepted digital twin models as replacements for control arms in clinical trials. The industry is no longer asking whether to build Digital Health Twins. It is asking how.
CaraOmics Founded
CaraOmics launches in Amsterdam to close the infrastructure gap. An EU-sovereign MLOps platform purpose-built for Digital Health Twin development, with regulatory compliance embedded from day one. The missing layer between research and patient impact.
Patient data deserves the highest standard of protection. Our infrastructure is EU-sovereign by design, built on European cloud with full GDPR, AI Act, and MDR alignment. Based in Amsterdam, home of the European Medicines Agency, we operate at the regulatory centre of global life sciences.
For organisations worldwide, that sovereignty is not a limitation. It is the strongest data governance foundation available for building Digital Health Twins.
